1. The antihypertensive effect of the new drug, SKF 92 657, a hydrazinopyridazine derivative, possessing both β-adrenoreceptor-blocking and vasodilating properties, was investigated in essential hypertension.

2. Single oral doses of 1.0 or 2.0 mg/kg did not produce any consistent decrease in blood pressure; 4.0 mg/kg was the threshold dose for a mild but not significant blood pressure reduction, whereas 8.0 mg/kg caused a significant and marked blood pressure decrease without clinically relevant changes in heart rate.

3. Continued administration of the drug for 7 days induced a significant and uniform reduction in blood pressure without tachycardia. The increase in systolic blood pressure and in heart rate caused by dynamic exercise was left unaffected by the drug.

This content is only available as a PDF.
You do not currently have access to this content.